Fig. 7: Proposed model of how TCR Vβ-targeting CAR-T cell treatment eliminates T cell malignancies and maintains sufficient T cell-mediated immunity.
From: T cell receptor β-chain-targeting chimeric antigen receptor T cells against T cell malignancies
T cell malignancies are mostly monoclonal or oligoclonal. When pan T cell markers are used for CAR-T cell targets, CAR-T cells eliminate both malignant T cells and normal T cells. This strategy will cause T cell aplasia in the host and weak immune responses against vaccination, infection and tumor cells. When TCR Vβ subtypes are used for CAR-T cell targets, CAR-T cells eliminate malignant T cells and a small portion of normal T cells. This strategy will maintain sufficient T cell-mediated immunity during vaccination, infection and tumor control. The cartoons in this figure were created with BioRender (http://biorender.com/).
